Association study of MIA3 rs17465637 polymorphism with cardiovascular disease in rheumatoid arthritis patients
Mercedes García-Bermúdez1, Raquel López-Mejías, Carlos González-Juanatey
1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain.
Abstract:
Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis. Melanoma inhibitor protein 3 (MIA3) is required for the export of collagen VlI (COL7A1) from the endoplasmic reticulum and it appears to be a tumor suppressor of malignant melanoma. Genome-wide association studies have described an association between MIA3 rs17465637 A/C polymorphisms and coronary artery disease and myocardial infarction. Because of that, we assessed the MIA3 rs17465637 polymorphism in 1505 RA Spanish patients stratified according to the presence/absence of cardiovascular (CV) disease. Also, a subgroup of patients without CV events was assessed for the presence of subclinical atherosclerosis using carotid ultrasound to establish carotid intima-media wall thickness and carotid plaques and brachial ultrasonography to determine the presence of endothelial dysfunction by flow-mediated endothelium-dependent and independent vasodilatation. MIA3 rs17465637 allele A showed a trend for association with the presence of carotid plaques (odds ratio 1.56, 95% confidence interval [0.96-2.51]; p=0.07). However, apart from an association of the MIA3 rs17465637 A allele with the risk of CV events in RA patients with dyslipidemia (p=0.018), no other significant associations were found between the presence of MIA3 rs17465637 A allele and the risk of suffering CV events or other surrogate markers of atherosclerosis. In conclusion, our results suggest a potential association of the MIA3 rs17465637 with CV disease in dyslipidemic patients with RA. However, additional studies are required to better establish the role of the MIA3 gene in mechanisms leading to the accelerated atherogenesis observed in RA.
Insights
The MIA3 rs17465637 A allele may increase cardiovascular event risk in rheumatoid arthritis (RA) patients with dyslipidemia. Further research is needed to confirm the MIA3 gene
Area of Science:
- Genetics and Cardiovascular Disease
- Rheumatology and Immunology
Background:
- Rheumatoid arthritis (RA) is linked to accelerated atherosclerosis.
- Melanoma inhibitor protein 3 (MIA3) gene variants have been associated with cardiovascular disease.
- The role of MIA3 in RA-associated cardiovascular complications is unclear.
Purpose of the Study:
- To investigate the association of the MIA3 rs17465637 polymorphism with cardiovascular disease in Spanish rheumatoid arthritis patients.
- To evaluate subclinical atherosclerosis markers in relation to the MIA3 polymorphism.
Main Methods:
- Genotyping of the MIA3 rs17465637 polymorphism in 1505 RA patients.
- Stratification based on cardiovascular disease presence.
- Carotid and brachial ultrasonography to assess subclinical atherosclerosis and endothelial dysfunction.
Main Results:
- A trend for association between MIA3 rs17465637 allele A and carotid plaques (p=0.07).
- Significant association of the MIA3 rs17465637 A allele with cardiovascular event risk in RA patients with dyslipidemia (p=0.018).
- No other significant associations found between the MIA3 allele A and cardiovascular events or atherosclerosis markers.
Conclusions:
- The MIA3 rs17465637 polymorphism may be associated with cardiovascular disease risk in rheumatoid arthritis patients, particularly those with dyslipidemia.
- Further studies are required to elucidate the role of MIA3 in RA-associated atherogenesis.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Imaging Studies for Cardiovascular System IV: CMRI
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management
